Related Links

Javascript Error

Your browser JavaScript is turned off causing certain features of the NIAID Institute of Allergy and Infectious Diseases web site to work incorrectly. Please visit your browser settings and turn JavaScript on.
Read more information on enabling JavaScript.

Lyme Disease

Vaccines

Background

Two large pharmaceutical companies have devoted considerable effort to developing a vaccine for Lyme disease, but there are no vaccines for humans available in the United States today.

Double-blind, randomized, placebo-controlled clinical trials—the most rigorous type of clinical trial used today— have been completed for each of two Borrelia burgdorferi vaccines manufactured by GlaxoSmithKline [(GSK), formerly SmithKline Beecham (SKB)], and Pasteur Merieux Connaught. Each study involved more than 10,000 volunteers from areas of the United States where Lyme disease is common.

Both vaccines were based on a specific part of B. burgdorferi called outer surface protein A (OspA). They were found to be between 49 and 68 percent effective in preventing Lyme disease after two injections, and 76 to 92 percent effective in preventing Lyme disease after three injections. The duration of the protective immunity generated in response to the vaccines is not known. The SKB vaccine was ultimately licensed as LYMErix and approved by the Food and Drug Administration (FDA) in December 1998.

NIAID was not directly involved in the design and implementation of these particular vaccine trials. However, patents for cloning the genes used in making the vaccine, as well as knowledge of how certain antibodies contribute to protective immunity, were derived from basic research grants funded by NIAID.

In April 2002, GSK announced that even with the incidence of Lyme disease continuing to rise, sales for LYMErix declined from about 1.5 million doses in 1999 to a projected 10,000 doses in 2002. Although studies conducted by FDA failed to reveal that any reported adverse events were vaccine-associated, GSK discontinued manufacturing the vaccine (Vaccine 20: 1603, 2002).

In 2013, Baxter Biosciences (Vienna, Austria) reported the development and clinical testing of a new multivalent vaccine for Lyme disease in humans (Lancet Infect Dis 13: 680, 2013).

NIAID Research

Reservoir-based approaches

Infectious disease reservoirs are what scientists call the places or populations that harbor disease-causing pathogens. For example, certain types of wildlife can be long-term carriers, or hosts, of a disease. Rodents are a major reservoir for Lyme disease, so scientists have been looking at ways to prevent them from getting infected with B. burgdorferi. Stopping the bacterial infection in rodents could potentially prevent transmission of the bacteria to the ticks that depend on the rodents in their early life cycle, and, therefore, from ticks to humans.

NIAID-funded investigators have developed an experimental bait—and vaccine—delivery system. In a study, mice were given this vaccine-laced bait then exposed to Ixodes ticks carrying multiple strains of B. burgdorferi. Oral vaccination was found to protect 89 percent of the mice from infection and the blood tests showed their immune systems created antibodies to the Lyme bacteria (Clin Vaccine Immunol 18: 1809, 2011).

NIAID is part of a collaborative effort with researchers at Ventria Bioscience and the Centers for Disease Control and Prevention who are supporting a similar approach. Scientists are working to grow rice plants that contain vaccine elements that could eventually be fed to rodent populations, thus blocking the transmission cycle of the disease from rodents to ticks to people. These findings are consistent with the results reported by other investigators (Proc Natl Acad Sci 52: 18159, 2004).

In other studies, NIAID grantees have developed a mouse-targeted vaccine using Vaccinia virus. Oral vaccination of mice with a single dose of the vaccine resulted in strong immune system response and full protection from B. burgdorferi infection among vaccinated mice. In addition, scientists observed a significant clearance of B. burgdorferi from infected ticks who fed on vaccinated mice (Vaccine 24: 1949, 2006). These findings indicate that such a vaccine may effectively reduce the incidence of Lyme disease in endemic areas.

Human Vaccine Development

NIAID supports significant research efforts focused on human vaccination against Lyme disease. Ongoing research projects include the development of a new, second-generation vaccine for human Lyme disease; studies to test the vaccine in mice are underway. NIAID also supports multiple research projects in early-stage discovery and characterization of novel vaccine targets, including tick saliva-based approaches.